Acadia Pharmaceuticals price target raised to $95 from $93 at Credit Suisse

Credit Suisse analyst A.J. Rice raised the firm’s price target on Acadia Pharmaceuticals to $95 from $93 and keeps an Outperform rating on the shares. The company reported an improvement in labor expense at the facility level in Q1, and addressed the expected impact of redeterminations within Medicaid, which accounts for 51.8% of the company’s revenue, the analyst tells investors in a research note. While Acadia reported a strong start to the year, potential headwinds loom, the firm says.